Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
135.4 USD | -0.95% | -2.86% | +2.77% |
May. 31 | Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing | MT |
May. 28 | Neurocrine Biosciences Says CEO Kevin Gorman Retiring | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 58% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- With an expected P/E ratio at 33.37 and 21.36 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.77% | 13.63B | C+ | ||
+11.60% | 106B | B+ | ||
-4.68% | 24.28B | B+ | ||
-0.03% | 21.96B | B | ||
-8.05% | 18.16B | A- | ||
-42.12% | 16.37B | A- | ||
-17.47% | 15.56B | B | ||
+34.58% | 12.27B | C+ | ||
+77.64% | 8.87B | C | ||
+7.26% | 7.75B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NBIX Stock
- Ratings Neurocrine Biosciences, Inc.